215 related articles for article (PubMed ID: 32418079)
1. Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
Oseni TO; Smith BL; Lehman CD; Vijapura CA; Pinnamaneni N; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4459-4465. PubMed ID: 32418079
[TBL] [Abstract][Full Text] [Related]
2. Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.
Grimm LJ; Ryser MD; Partridge AH; Thompson AM; Thomas JS; Wesseling J; Hwang ES
Ann Surg Oncol; 2017 Nov; 24(12):3534-3540. PubMed ID: 28795370
[TBL] [Abstract][Full Text] [Related]
3. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
5. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
6. Surgical upstaging rates in patients meeting the eligibility for active surveillance trials.
Iwamoto N; Nara M; Horiguchi SI; Aruga T
Jpn J Clin Oncol; 2021 Aug; 51(8):1219-1224. PubMed ID: 34091677
[TBL] [Abstract][Full Text] [Related]
7. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
8. Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed Low Risk DCIS Trial (LORIS).
Soumian S; Verghese ET; Booth M; Sharma N; Chaudhri S; Bradley S; Umranikar S; Millican-Slater RA; Hanby AM; Francis A
Eur J Surg Oncol; 2013 Dec; 39(12):1337-40. PubMed ID: 24209431
[TBL] [Abstract][Full Text] [Related]
9. Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.
Alaeikhanehshir S; Voets MM; van Duijnhoven FH; Lips EH; Groen EJ; van Oirsouw MCJ; Hwang SE; Lo JY; Wesseling J; Mann RM; Teuwen J;
Cancer Imaging; 2024 Apr; 24(1):48. PubMed ID: 38576031
[TBL] [Abstract][Full Text] [Related]
10. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
11. Atypical Ductal Hyperplasia and Those Bordering on Ductal Carcinoma In Situ Should Be Included in the Active Surveillance Clinical Trials.
Khoury T; Jabbour N; Peng X; Yan L; Quinn M
Am J Clin Pathol; 2020 Jan; 153(1):131-138. PubMed ID: 31602455
[TBL] [Abstract][Full Text] [Related]
12. Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ.
Grimm LJ; Ghate SV; Hwang ES; Soo MS
Acad Radiol; 2017 Nov; 24(11):1364-1371. PubMed ID: 28705686
[TBL] [Abstract][Full Text] [Related]
13. Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma.
Lamb LR; Kim G; Oseni TO; Bahl M
Acad Radiol; 2021 Mar; 28(3):e71-e76. PubMed ID: 32222328
[TBL] [Abstract][Full Text] [Related]
14. Preoperatively diagnosed ductal cancers in situ of the breast presenting as even small masses are of high risk for the invasive cancer foci in postoperative specimen.
Szynglarewicz B; Kasprzak P; Halon A; Matkowski R
World J Surg Oncol; 2015 Jul; 13():218. PubMed ID: 26179898
[TBL] [Abstract][Full Text] [Related]
15. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!
Marques LC; Marta GN; de Andrade JZ; Andrade D; de Barros ACSD; Andrade FEM
Eur J Surg Oncol; 2019 Jul; 45(7):1152-1155. PubMed ID: 30665684
[TBL] [Abstract][Full Text] [Related]
16. Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?
Miller-Ocuin JL; Howard-McNatt M; Levine EA; Chiba A
Am Surg; 2020 Aug; 86(8):955-957. PubMed ID: 32862671
[TBL] [Abstract][Full Text] [Related]
17. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.
Nicholson S; Hanby A; Clements K; Kearins O; Lawrence G; Dodwell D; Bishop H; Thompson A;
Eur J Surg Oncol; 2015 Jan; 41(1):86-93. PubMed ID: 25441934
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
19. Sentinel Node Procedure Obsolete in Lumpectomy for Ductal Carcinoma In Situ.
Heymans C; van Bastelaar J; Visschers RGJ; Vissers YLJ
Clin Breast Cancer; 2017 Jun; 17(3):e87-e93. PubMed ID: 28162949
[TBL] [Abstract][Full Text] [Related]
20. Preoperative breast MRI in management of patients with needle biopsy-proven ductal carcinoma in situ (DCIS).
van Bekkum S; Ter Braak BPM; Plaisier PW; van Rosmalen J; Menke-Pluijmers MBE; Westenend PJ
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1854-1860. PubMed ID: 32624292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
